Profile picture

Doctor Aoife Gowran

Monzino Cardiology Centre, Milan (Italy)
Follow
Biography
In 2014 Aoife moved from Dublin to Milan where she established the an induced pluripotent stem cells (iPSC) research program and iPSC Group in the Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino. The iPSC Group works together to create cutting-edge precision models of cardiomyopathy and also investigates the value of bio-engineered substrates and microfluidic platforms to benefit both the cell maturity and disease-model faithfulness. Recently, her group has received major funding from EU, national and private enterprise sources (European Research Area Network on Cardiovascular Diseases, Fondazione Telethon, Unione Italiana Lotta alla Distrofia Muscolare, Italian Ministry of Health, Umberto Veronesi Foundation, Fondazione IEO-CCM, Italfarmaco s.r.l.). She continues to collaborate with investigators in Italy and abroad.
Logo ESC

Contributor content

The cannabinoid receptor type two is a therapeutic target for muscular dystrophy cardiomyopathy.
Presentation
The cannabinoid receptor type two is a therapeutic target for muscular dystrophy cardiomyopathy.
The endocannabinoid system is a novel therapeutic target for muscular dystrophy cardiomyopathy.
Presentation
The endocannabinoid system is a novel therapeutic target for muscular dystrophy cardiomyopathy.
The role of the endocannabinoid system in modelling muscular dystrophy cardiac disease with induced pluripotent stem cells.
Presentation
The role of the endocannabinoid system in modelling muscular dystrophy cardiac disease with induced pluripotent stem cells.

ESC 365 is supported by